{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:51:29Z","timestamp":1792651889896,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81600107"],"award-info":[{"award-number":["81600107"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100230"],"award-info":[{"award-number":["82100230"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["1708085MH180"],"award-info":[{"award-number":["1708085MH180"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["WK9110000168"],"award-info":[{"award-number":["WK9110000168"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.biopha.2022.113527","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T18:27:06Z","timestamp":1660328826000},"page":"113527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia"],"prefix":"10.1016","volume":"153","author":[{"given":"Anyou","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingmeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baolin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanglai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.biopha.2022.113527_bib1","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.113527_bib2","series-title":"SEER Cancer Statistics Review, 1975\u20132016","year":"2019"},{"issue":"14","key":"10.1016\/j.biopha.2022.113527_bib3","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des My\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2022.113527_bib4","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/10428194.2020.1719098","article-title":"Venetoclax in acute myeloid leukemia-current and future directions","volume":"61","author":"Lachowiez","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.biopha.2022.113527_bib5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","article-title":"Towards precision medicine for AML","volume":"18","author":"D\u00f6hner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2022.113527_bib6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.biopha.2022.113527_bib7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conVentional care regimens in older patients with newly diagnosed AML with >\u200930\u2009% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.113527_bib8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conVentional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2022.113527_bib9","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2022.113527_bib10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113527_bib11","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2022.113527_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-022-01229-z","article-title":"Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure","volume":"15","author":"Short","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2022.113527_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.biopha.2022.113527_bib14","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1002\/ajh.25146","article-title":"Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.biopha.2022.113527_bib15","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113527_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","article-title":"Emerging agents and regimens for AML","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2022.113527_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2013.07.012","article-title":"A kinaseindependent function of CDK6 links the cell cycle to tumor angiogenesis","volume":"24","author":"Kollmann","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2022.113527_bib18","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood-2015-11-683581","article-title":"Palbociclib treatment of FLT3-ITD 1 AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6","volume":"27","author":"Uras","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.biopha.2022.113527_bib19","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.3390\/ijms21072528","article-title":"CDK6 inhibition: a novel approach in AML management","volume":"21","author":"Uras","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2022.113527_bib20","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1002\/ijc.33054","article-title":"The role of CDK6 in cancer","volume":"147","author":"Nebenfuehr","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2022.113527_bib21","first-page":"1","article-title":"GENT2: an updated gene expression database for normal and tumor tissues","volume":"12","author":"Park","year":"2019","journal-title":"BMC Med. Genom."},{"issue":"1","key":"10.1016\/j.biopha.2022.113527_bib22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/blood-2014-06-584417","article-title":"CDK6 as a key regulator of hematopoietic and leukemic stem cell activation","volume":"125","author":"Scheicher","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.113527_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2014-11-609230","article-title":"CDK6 is a regulator of stem cells \u2018Egr\u2019 to wake up","volume":"125","author":"Guzman","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.113527_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2014-02-558114","article-title":"Requirement for CDK6 in MLL-rearranged acute myeloid leukemia","volume":"124","author":"Placke","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.biopha.2022.113527_bib25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003267","article-title":"CDK6 is an essential direct target of NUP98-fusion proteins in acute myeloid leukemia","volume":"136","author":"Schmoellerl","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.113527_bib26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.biopha.2022.113527_bib27","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/bloodadvances.2018019398","article-title":"Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia","volume":"2","author":"Matsuo","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.biopha.2022.113527_bib28","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.V128.22.1608.1608","article-title":"CDK4\/6 inhibitor palbociclib for treatment of KMT2A-rearranged acute myeloid leukemia: interim analysis of the AMLSG 23-14 trial","volume":"128","author":"Fr\u00f6hling","year":"2016","journal-title":"Blood"},{"issue":"Suppl. S1","key":"10.1016\/j.biopha.2022.113527_bib29","doi-asserted-by":"crossref","first-page":"S4057","DOI":"10.1182\/blood-2018-99-117334","article-title":"Phase I study of palbociclib alone and in combination in patients with relapsed and refractory (R\/R) leukemias","volume":"132","author":"Kadia","year":"2018","journal-title":"Blood"},{"issue":"Suppl._1","key":"10.1016\/j.biopha.2022.113527_bib30","doi-asserted-by":"crossref","first-page":"S878","DOI":"10.1182\/blood-2019-126020","article-title":"Patterns of sensitivity exhibited by venetoclax-inclusive drug combinations in acute myeloid leukemia","volume":"134","author":"Kurtz","year":"2019","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.biopha.2022.113527_bib31","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1182\/blood-2018-175","article-title":"Biomarkers predicting venetoclax sensitivity and strategies for venetoclax combination treatment","volume":"132","author":"Zhang","year":"2018","journal-title":"Blood"},{"issue":"63","key":"10.1016\/j.biopha.2022.113527_bib32","doi-asserted-by":"crossref","first-page":"107206","DOI":"10.18632\/oncotarget.22284","article-title":"Combined venetoclax and alvocidib in acute myeloid leukemia","volume":"8","author":"Bogenberger","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2022.113527_bib33","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41392-021-00776-0","article-title":"Restoration of HBV-specific CD8+ T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-\u03b1 therapy","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"10","key":"10.1016\/j.biopha.2022.113527_bib34","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/jmcb\/mjab067","article-title":"Transcriptomic characteristics and impaired immune function of patients who retest positive for SARS-CoV-2 RNA","volume":"13","author":"Wang","year":"2021","journal-title":"J. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113527_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41420-021-00496-y","article-title":"Interrogation of novel CDK2\/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML","volume":"7","author":"Chantkran","year":"2021","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.biopha.2022.113527_bib36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ebiom.2019.07.058","article-title":"Hepatectomy promotes recurrence of liver cancer by enhancing IL-11-STAT3 signaling","volume":"46","author":"Wang","year":"2019","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.biopha.2022.113527_bib37","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1002\/ijc.33054","article-title":"The role of CDK6 in cancer","volume":"147","author":"Nebenfuehr","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2022.113527_bib38","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/blood-2014-06-584417","article-title":"CDK6 as a key regulator of hematopoietic and leukemic stem cell activation","volume":"125","author":"Scheicher","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.113527_bib39","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2007-02-071266","article-title":"Pharmacologic inhibition of CDK4\/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia","volume":"110","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.113527_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2014-02-558114","article-title":"Requirement for CDK6 in MLL-rearranged acute myeloid leukemia","volume":"124","author":"Placke","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.113527_bib41","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00277-021-04747-x","article-title":"Genetic diversity within leukemia-associated immunophenotype-defined subclones in AML","volume":"101","author":"Tiso","year":"2022","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113527_bib42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/leu.2017.243","article-title":"Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1","volume":"32","author":"Teh","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2022.113527_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169128","article-title":"Selective inhibitors of histone deacetylases 1 and 2 synergize with azacitidine in acute myeloid leukemia","volume":"12","author":"Min","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.biopha.2022.113527_bib44","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3390\/cancers12061596","article-title":"Targeting pharmacokinetic drug resistance in acute myeloid leukemia cells with CDK4\/6 inhibitors","volume":"12","author":"Sorf","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2022.113527_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.biopha.2022.113527_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"26","key":"10.1016\/j.biopha.2022.113527_bib47","doi-asserted-by":"crossref","first-page":"23681","DOI":"10.1074\/jbc.M100279200","article-title":"Novel role for JNK as a stress-activated Bcl2 kinase","volume":"276","author":"Deng","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113527_bib48","first-page":"1","article-title":"Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015\u20132020","author":"Huntington","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.biopha.2022.113527_bib49","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(20)30642-2","article-title":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","volume":"22","author":"Mayer","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113527_bib50","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41420-022-00884-y","article-title":"Aberrantly expressed Wnt5a in nurse-like cells drives resistance to venetoclax in chronic lymphocytic leukemia","volume":"8","author":"Guo","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.biopha.2022.113527_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-021-01502-z","article-title":"Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL","author":"Seyfried","year":"2022","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.biopha.2022.113527_bib52","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222009167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222009167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:34:18Z","timestamp":1779968058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222009167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":52,"alternative-id":["S0753332222009167"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113527","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113527"}}